TY - JOUR
T1 - Prevalence of Cerebrotendinous Xanthomatosis among Patients Diagnosed with Acquired Juvenile-Onset Idiopathic Bilateral Cataracts
AU - Freedman, Sharon F.
AU - Brennand, Charlotte
AU - Chiang, John
AU - Debarber, Andrea
AU - Del Monte, Monte A.
AU - Duell, P. Barton
AU - Fiorito, John
AU - Marshall, Randall
N1 - Funding Information:
a former employee of Retrophin, Inc, and was responsible for the operationalization of the study. Dr Chiang is a minority owner of Molecular Vision Laboratory. Dr DeBarber has received grants, personal fees, and nonfinancial support from Retrophin, Inc, paid to her institution as well as personal fees from Leadiant Biosciences and has patent 14/401,427 issued. Dr Del Monte has received grants from Retrophin, Inc, paid to his institution. Dr Duell has received grants and personal fees from Esperion, Regeneron, Regenxbio, and Retrophin, Inc, and personal fees from Akcea and AstraZeneca. Mr Fiorito is an employee of Retrophin, Inc. Dr Marshall is a former employee of Retrophin, Inc. No other disclosures were reported.
Funding Information:
Funding/Support: This study was funded by
Funding Information:
Additional Contributions: We thank the patients and their parents for granting permission to publish this information. Medical writing and editorial support were provided by Sherri D. Jones, PharmD, and Donald Fallon, ELS, of MedVal Scientific Information Services, Princeton, New Jersey. They were funded by Retrophin, Inc.
Publisher Copyright:
© 2019 American Medical Association. All rights reserved.
PY - 2019/11
Y1 - 2019/11
N2 - Importance: Cerebrotendinous xanthomatosis (CTX) is a rare autosomal recessive bile acid synthesis disorder caused by mutations in CYP27A1, the gene encoding sterol 27-hydroxylase, which results in elevated levels of plasma cholestanol and urinary bile alcohols. Clinical symptoms and signs may include early-onset chronic diarrhea, juvenile-onset bilateral cataracts, cholestatic jaundice, tendon xanthomas, and progressive neurological deterioration. Although initiation of treatment at a young age can prevent disease complications, diagnosis often occurs after the onset of permanent neurologic damage. Strategies are needed to facilitate early diagnosis. Objective: To evaluate the prevalence of CTX in a patient population diagnosed with early-onset idiopathic bilateral cataracts. Design, Setting, and Participants: This interim analysis of the Cerebrotendinous Xanthomatosis Prevalence Study was conducted in 26 active US sites from November 2015 to June 2017. The study included patients diagnosed as having idiopathic bilateral cataracts from ages 2 to 21 years. Potentially eligible study participants were identified through retrospective medical record review or on receiving care for cataracts at an active site. Data were analyzed from July 2017 to October 2018. Main Outcomes and Measures: Measurement of plasma cholestanol levels and optional urine bile alcohol screening were performed. A plasma cholestanol concentration of 0.4 mg/dL or greater or a positive urine bile alcohol result prompted CYP27A1 genetic testing to confirm the diagnosis of CTX. Results: Of 170 tested patients, 88 (51.8%) were male, and the median (range) age was 10 (2-49) years. A total of 3 patients (1.8%) had biochemical and genetic confirmation of newly diagnosed CTX (plasma cholestanol level greater than 1.0 mg/dL, positive urine bile alcohol result, and disease-causative mutations in CYP27A1). The mean (range) age at cataract diagnosis for patients with CTX was 12 (8-16) years. Reported symptoms included abnormal gait or balance (n = 3), learning disability (n = 2), cognitive decline (n = 2), seizures (n = 2), frequent bone fractures (n = 2), and chronic diarrhea (n = 1). Conclusions and Relevance: To date, 1.8% of patients in this study were diagnosed as having CTX, which is approximately 500-fold the currently estimated prevalence of CTX in the general population (3 to 5 per 100000). These data suggest that juvenile-onset idiopathic bilateral cataracts may be useful as a screening marker for CTX and that ophthalmologists can play an important role in facilitating early identification of this condition..
AB - Importance: Cerebrotendinous xanthomatosis (CTX) is a rare autosomal recessive bile acid synthesis disorder caused by mutations in CYP27A1, the gene encoding sterol 27-hydroxylase, which results in elevated levels of plasma cholestanol and urinary bile alcohols. Clinical symptoms and signs may include early-onset chronic diarrhea, juvenile-onset bilateral cataracts, cholestatic jaundice, tendon xanthomas, and progressive neurological deterioration. Although initiation of treatment at a young age can prevent disease complications, diagnosis often occurs after the onset of permanent neurologic damage. Strategies are needed to facilitate early diagnosis. Objective: To evaluate the prevalence of CTX in a patient population diagnosed with early-onset idiopathic bilateral cataracts. Design, Setting, and Participants: This interim analysis of the Cerebrotendinous Xanthomatosis Prevalence Study was conducted in 26 active US sites from November 2015 to June 2017. The study included patients diagnosed as having idiopathic bilateral cataracts from ages 2 to 21 years. Potentially eligible study participants were identified through retrospective medical record review or on receiving care for cataracts at an active site. Data were analyzed from July 2017 to October 2018. Main Outcomes and Measures: Measurement of plasma cholestanol levels and optional urine bile alcohol screening were performed. A plasma cholestanol concentration of 0.4 mg/dL or greater or a positive urine bile alcohol result prompted CYP27A1 genetic testing to confirm the diagnosis of CTX. Results: Of 170 tested patients, 88 (51.8%) were male, and the median (range) age was 10 (2-49) years. A total of 3 patients (1.8%) had biochemical and genetic confirmation of newly diagnosed CTX (plasma cholestanol level greater than 1.0 mg/dL, positive urine bile alcohol result, and disease-causative mutations in CYP27A1). The mean (range) age at cataract diagnosis for patients with CTX was 12 (8-16) years. Reported symptoms included abnormal gait or balance (n = 3), learning disability (n = 2), cognitive decline (n = 2), seizures (n = 2), frequent bone fractures (n = 2), and chronic diarrhea (n = 1). Conclusions and Relevance: To date, 1.8% of patients in this study were diagnosed as having CTX, which is approximately 500-fold the currently estimated prevalence of CTX in the general population (3 to 5 per 100000). These data suggest that juvenile-onset idiopathic bilateral cataracts may be useful as a screening marker for CTX and that ophthalmologists can play an important role in facilitating early identification of this condition..
UR - http://www.scopus.com/inward/record.url?scp=85072515541&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85072515541&partnerID=8YFLogxK
U2 - 10.1001/jamaophthalmol.2019.3639
DO - 10.1001/jamaophthalmol.2019.3639
M3 - Article
C2 - 31536098
AN - SCOPUS:85072515541
SN - 2168-6165
VL - 137
SP - 1312
EP - 1316
JO - JAMA ophthalmology
JF - JAMA ophthalmology
IS - 11
ER -